ALK inhibitors beginning with crizotinib were first approved by the FDA in 201117, with clinical trials quickly demonstrating the superiority of ALK inhibitors over chemotherapy for ALK+ NSCLC treatment18. Here, ALK is linked to non-small cell lung carcinoma.